Kristi Rosa

The United Kingdom’s National Institute for Health and Care Excellence has chosen to not recommend the combination of pembrolizumab and axitinib for use in treatment-naïve adult patients with advanced renal cell carcinoma.

Faculty from NewYork-Presbyterian Hospital/Columbia University Irving Medical Center share their resolutions for the new year and the efforts being made to improve patient outcomes in practice.

Peter Voorhees, MD, provides an overview of the many developments made with CAR T-cell therapy in multiple myeloma, as well as the exciting research being done with bispecific antibodies

Following significant progress made in the development of novel systemic therapies for patients with cancer, the role of surgery in oncology continues to evolve. To this end, ASCO has selected the refinement of surgical treatment of cancer as its Advance of the Year.

Kevin Kalinsky, MD, MS, highlights recent developments in triple-negative breast cancer, including the potential role of immunotherapy in the neoadjuvant setting.

The FDA has scheduled an Oncologic Drugs Advisory Committee hearing for February 26, 2020, to discuss data supporting a supplemental biologics license application for intravenous ramucirumab injection for use in combination with erlotinib in the frontline treatment of patients with metastatic non–small cell lung cancer whose tumors harbor EGFR Ex19del or Ex21 substitution mutations.

The Centers for Medicare & Medicaid Services has expanded coverage of laboratory diagnostic tests that utilize next-generation sequencing that have been approved or cleared by the FDA for use in patients with germline ovarian or breast cancers.

Rebecca L. Olin, MD, MSCE, sheds light on the pivotal progress made in acute myeloid leukemia treatment in recent years.

Three biosimilars—bevacizumab-bvzr (Zirabev), rituximab-pvvr (Ruxience), and trastuzumab-qyyp)—will become available in the United States at a substantial discount to their reference products.

The National Institute for Health and Care Excellence does not recommend larotrectinib for the treatment of advanced NTRK fusion–positive solid tumors in adults and children without satisfactory treatment options.

Anna C. Pavlick, DO, discusses key trials that have shed light on how to best treat patients with newly diagnosed, metastatic melanoma.

The United Kingdom’s National Institute for Health and Care Excellence has issued guidelines recommending against pembrolizumab for use in treatment-naïve patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma whose tumors express PD-L1 with a combined positive score of ≥1.

The National Institute for Health and Care Excellence has recommended the use of olaparib as a maintenance treatment in adults with relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Experts from The Ohio State University Comprehensive Cancer Center–James highlighted exciting research being conducted at their institution.

Pablo Ferraro, MD, discusses some of the latest developments in pancreatic cancer treatment and the potential role of emerging modalities under exploration.

Faculty from a 2019 OncLive® State of the Science Summit™ on Gastrointestinal Malignancies highlight the exciting research being conducted at their respective institutions.

Internationally renowned medical oncologist Thomas J. Lynch Jr, MD, has been named the new president and director of the Fred Hutchinson Cancer Research Center.

Jean L. Koff, MD, MS, highlights exciting advances made in follicular lymphoma and the promise of CAR T-cell therapies in other lymphoma subtypes.

Ajay K. Nooka, MD, MPH, FACP, discusses the shift in induction regimens in multiple myeloma and the impact of daratumumab (Darzalex) on the space.

Faculty from Memorial Sloan Kettering Cancer Center shed light on some of the intriguing research in hematologic cancer being conducted at their institution.

Residual cancer burden after neoadjuvant chemotherapy has been shown to be an accurate long-term predictor of disease recurrence and survival across all breast cancer subtypes.

Accelerated partial breast irradiation using intensity-modulated radiotherapy is not significantly different from whole breast irradiation in preventing recurrence in patients with low-risk early breast cancer.

The FDA has approved 2 abbreviated new drug applications for everolimus (Afinitor) tablets for the treatment of patients with select malignancies.

Daniel Stover, MD, discusses unmet needs in patients with ESR1-mutant breast cancer, his hopes for lasofoxifene in that setting, and ongoing research efforts examining novel agents and approaches in the pipeline.

Experts from West Cancer Center highlighted the exciting research being conducted at their institution.

Christine Bestvina, MD, discusses immunotherapy options in squamous non–small cell lung cancer, unanswered questions regarding patient selection, and directions for future research.

John Hays, MD, PhD, discusses ongoing research with immunotherapy in ovarian cancer, challenges with determining predictive biomarkers of response, and promising emerging modalities.

Jeremy Segal, MD, PhD, discusses pathologic considerations in non–small cell lung cancer and the evolving role of molecular testing.

Experts from The Ohio State University and Allegheny Health Network discuss the exciting research being conducted at their institutions.

David Morris, MD, FACS, provides an update on the 3 newest agents available for nonmetastatic castration-resistant prostate cancer treatment and discussed factors to consider when choosing among them.